All sponsors

Alkermes, Inc. $ALKS

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING7
READOUTS ≤12 MONTHS6
Open Alkermes, Inc. on the live radar map → 📅 $ALKS readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
OLZ/SAM
NCT05303064
P3RecruitingSchizophrenia; Bipolar I Disorder2202026-09
Vibrance-3
NCT06843590
P2Active, not recruitingIdiopathic Hypersomnia1262026-11 (+7 mo)
Brilliance NT1
NCT07455383
P3RecruitingNarcolepsy Type 11502027-05
Brilliance NT2
NCT07502443
P3RecruitingNarcolepsy Type 21762027-05
ALKS 2680 Dose 1
NCT07540897
P3RecruitingNarcolepsy Type 11502027-06
ALKS 7290
NCT07755410
P2RecruitingAttention Deficit Disorder With Hyperactivity (ADHD)3122027-07
OLZ/SAM
NCT04987229
P3Enrolling by invitationBipolar I Disorder; Schizophrenia2362027-09
ALKS 7290 Dose
NCT07901179
P2RecruitingMajor Depressive Disorder (MDD)1802028-01
ALKS 2680, 4mg
NCT06767683
P2/3RecruitingNarcolepsy Type 1; Narcolepsy Type 27862030-06 (+31 mo)